How Much Risk Should Big Pharma Accept To Close Deals In China?
Executive Summary
On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.
You may also be interested in...
San Francisco-based FibroGen Gets SFDA Nod Through Green Channel Procedure
HONG KONG - San Francisco-based FibroGen announced that Chinese regulators approved the start of clinical trials of novel therapy FG-4592 for anemia associated with chronic kidney disease. The approval was expedited through China's two-year-old special approval procedure, or "green channel.
The Year Of The Tiger Looking Strong For IPOs In China Following Sinopharm Success
HONG KONG - Concerns over valuation seem to be doing little to dampen enthusiasm for new Chinese pharmaceutical related stocks and the result is a minefield of opportunities on very shaky ground
Asia Spotlight: China Eclipses Japan To Become Second Largest Pharma Market
Despite a slowdown, China’s pharma market passed Japan in 2013, two years faster than expected.